Business
ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval
ANKTIVA® reaches U.S. commercial and Medicare insurance coverage milestone within three months of FDA approval Global expansion of commercial and clinical
About this update from Immunitybio, Inc.
[{"type":"text","content":"\n\nANKTIVA® reaches U.S. commercial and Medicare insurance coverage milestone within three months of FDA approval\n\n\n\nGlobal expansion of commercial and clinical bladder cancer programs\n\n\nFiling process initiated with European Medicines Agency (EMA) for regulatory approval of ANKTIVA in European Union countries\n\n\n\nGlobal filing for BCG naïve trial initiated (QUILT-2.005) in India\n\n\n\n\n\n\nANKTIVA Non-Small Cell Lung Cancer (NSCLC) FDA meeting held in June 2024\n\n\n\n \n\n\n CULVER CITY, Calif.--(BUSINESS WIRE)--\nImmunityBio, Inc. (NASDAQ: IBRX), today announced significant progress in market access, making ANKTIVA® (nogapendekin alfa inbakicept-pmln) widely available to patients through both commercial and government insurance programs. The company also announced plans to expand its bladder cancer program globally, notably in the European Union and India.\n\n\nCommercial Update\n\n\nImmunityBio’s commercial team continues to execute on key market access initiatives, which have resulted in more than 100 million medical lives being covered by medical reimbursement policies that include eligibility for ANKTIVA reimbursement since the therapeutic became available and was added to the National Comprehensive Cancer Network (NCCN) guidelines in May 2024. The company anticipates that it will achieve agreements to extend the number of lives covered in the coming months, and is currently working with the top insurance plans and academic institutions in the U.S. to increase ANKTIVA accessibility. This availability and reimbursement together have enabled the first patients to begin receiving ANKTIVA within eight weeks of FDA approval and resulted in initial product revenue for the company primarily in the last 30 days of Q2.\n\n\n“We are encouraged by the keen interest that physicians are showing in ANKTIVA as a treatment option for their patients with non-muscle invasive bladder cancer with carcinoma in situ (CIS), as well as by our conversations with payers as we see them adding our approved product into their policies,” said Richard Adcock, President and CEO of ImmunityBio. “Our team continues to focus on streamlining the processes for bringing this specialty medication to more qualified patients. We are acutely aware that with cancer, every day matters.”\n\n\nEuropean Regulatory Filing\n\n\nImmunityBio has begun the fil...